The European Crohn’s and Colitis Organisation (ECCO) has officially included Evinature’s CurQD® Protocol in its 2025 Guidelines on Dietary Management of IBD, published in the Journal of Crohn’s & Colitis in September 2025.
What ECCO Represents
The ECCO Guidelines are among the most trusted and influential clinical resources in global gastroenterology.
Developed by leading international experts, they guide how physicians around the world diagnose and treat Crohn’s disease and ulcerative colitis, shaping the standard of care for millions of patients.
Being included in these guidelines means CurQD® has earned recognition from one of the highest authorities in IBD medicine — a defining step in its integration into mainstream clinical practice.
From Congress to Publication
This milestone follows CurQD®’s first presentation at the ECCO Congress in Berlin in February 2025 — the world’s leading scientific forum for inflammatory bowel disease.
At the conference, CurQD® was featured among emerging, evidence-based nutritional and adjunct therapies for ulcerative colitis and Crohn’s disease, paving the way for its formal inclusion in ECCO’s published recommendations later that year.
Clinical Evidence Recognized
The guidelines cite findings from one of the first landmark studies conducted on CurQD®.
This multicenter, real-world study — carried out across five academic medical centers — was originally published in Alimentary Pharmacology & Therapeutics in 2023 and republished in the Journal of Crohn’s & Colitis in 2025.
The research evaluated the use of CurQD® in adults with active ulcerative colitis, including patients who had previously been exposed to, or even failed, biologic and small-molecule therapies.
By demonstrating similar levels of clinical success without the high cost or side-effect profile associated with conventional biologics, the study positioned CurQD® as a groundbreaking adjunct therapy for ulcerative colitis — expanding treatment options and providing renewed hope for patients seeking sustainable remission.
ECCO also referenced a European prospective study, published in Inflammatory Bowel Diseases in 2025, which examined the combined use of Vedolizumab and CurQD® in patients with active ulcerative colitis. This research offered early evidence that CurQD® can act synergistically with biologics, optimizing treatment outcomes while reducing the need for corticosteroids.
A Milestone for IBD Patients
For people living with IBD, this recognition carries profound meaning.
It marks the official acknowledgment of a safe, natural, and scientifically validated adjunct option within modern IBD treatment frameworks — one that complements conventional medicine while supporting long-term gut health and remission maintenance.
Advancing Integrative Care
CurQD®’s inclusion in the ECCO Guidelines represents a turning point for integrative IBD care.
It reinforces Evinature’s mission to bridge rigorous clinical research with natural, evidence-based solutions, empowering both patients and healthcare professionals to pursue safe, effective, and personalized paths to recovery and well-being.
Evinature
